Leap Therapeutics (LPTX) Competitors $0.30 +0.02 (+8.29%) Closing price 08/22/2025 04:00 PM EasternExtended Trading$0.30 0.00 (-0.94%) As of 08/22/2025 07:59 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsHeadlinesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock LPTX vs. DTIL, TELO, ENLV, SLGL, ATNF, ACRV, GBIO, PEPG, XCUR, and EGRXShould you be buying Leap Therapeutics stock or one of its competitors? The main competitors of Leap Therapeutics include Precision BioSciences (DTIL), Telomir Pharmaceuticals (TELO), Enlivex Therapeutics (ENLV), Sol-Gel Technologies (SLGL), 180 Life Sciences (ATNF), Acrivon Therapeutics (ACRV), Generation Bio (GBIO), PepGen (PEPG), Exicure (XCUR), and Eagle Pharmaceuticals (EGRX). These companies are all part of the "pharmaceutical products" industry. Leap Therapeutics vs. Its Competitors Precision BioSciences Telomir Pharmaceuticals Enlivex Therapeutics Sol-Gel Technologies 180 Life Sciences Acrivon Therapeutics Generation Bio PepGen Exicure Eagle Pharmaceuticals Precision BioSciences (NASDAQ:DTIL) and Leap Therapeutics (NASDAQ:LPTX) are both small-cap medical companies, but which is the better business? We will contrast the two companies based on the strength of their institutional ownership, risk, analyst recommendations, profitability, media sentiment, dividends, earnings and valuation. Do institutionals & insiders believe in DTIL or LPTX? 38.0% of Precision BioSciences shares are owned by institutional investors. Comparatively, 30.5% of Leap Therapeutics shares are owned by institutional investors. 4.5% of Precision BioSciences shares are owned by insiders. Comparatively, 7.5% of Leap Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth. Which has more volatility and risk, DTIL or LPTX? Precision BioSciences has a beta of 1.52, meaning that its share price is 52% more volatile than the S&P 500. Comparatively, Leap Therapeutics has a beta of -0.27, meaning that its share price is 127% less volatile than the S&P 500. Which has better earnings & valuation, DTIL or LPTX? Precision BioSciences has higher revenue and earnings than Leap Therapeutics. Precision BioSciences is trading at a lower price-to-earnings ratio than Leap Therapeutics, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioPrecision BioSciences$1.26M46.36$7.17M-$8.81-0.56Leap TherapeuticsN/AN/A-$67.56M-$1.58-0.19 Is DTIL or LPTX more profitable? Leap Therapeutics has a net margin of 0.00% compared to Precision BioSciences' net margin of -6,205.79%. Precision BioSciences' return on equity of -176.47% beat Leap Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets Precision BioSciences-6,205.79% -176.47% -69.05% Leap Therapeutics N/A -237.65%-155.38% Does the media favor DTIL or LPTX? In the previous week, Precision BioSciences' average media sentiment score of 1.21 beat Leap Therapeutics' score of 0.00 indicating that Precision BioSciences is being referred to more favorably in the media. Company Overall Sentiment Precision BioSciences Positive Leap Therapeutics Neutral Do analysts prefer DTIL or LPTX? Precision BioSciences currently has a consensus price target of $47.00, indicating a potential upside of 847.58%. Leap Therapeutics has a consensus price target of $3.38, indicating a potential upside of 1,033.31%. Given Leap Therapeutics' higher possible upside, analysts clearly believe Leap Therapeutics is more favorable than Precision BioSciences.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Precision BioSciences 0 Sell rating(s) 0 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 3.00Leap Therapeutics 0 Sell rating(s) 3 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 2.00 SummaryPrecision BioSciences beats Leap Therapeutics on 9 of the 14 factors compared between the two stocks. Get Leap Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for LPTX and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding LPTX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart LPTX vs. The Competition Export to ExcelMetricLeap TherapeuticsMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$11.40M$3.11B$5.75B$9.62BDividend YieldN/A2.23%4.40%4.10%P/E Ratio-0.1921.1431.2526.05Price / SalesN/A345.39433.91193.97Price / CashN/A43.1937.7358.48Price / Book2.138.129.536.61Net Income-$67.56M-$54.72M$3.26B$265.65M7 Day Performance11.08%2.62%2.13%2.03%1 Month Performance-16.63%2.68%2.80%-0.31%1 Year Performance-89.05%10.93%30.68%19.06% Leap Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)LPTXLeap Therapeutics2.1924 of 5 stars$0.30+8.3%$3.38+1,033.3%-89.1%$11.40MN/A-0.1940Short Interest ↓DTILPrecision BioSciences4.0691 of 5 stars$4.95+5.1%$47.00+849.5%-49.0%$55.52M$68.70M-0.56200Positive NewsTELOTelomir Pharmaceuticals2.6734 of 5 stars$1.49flat$15.00+906.7%-74.4%$44.35MN/A-2.761Gap DownENLVEnlivex Therapeutics3.3296 of 5 stars$1.25-31.3%$10.00+700.0%-18.6%$43.04MN/A-1.8970Upcoming EarningsShort Interest ↓High Trading VolumeSLGLSol-Gel Technologies1.0144 of 5 stars$16.10+4.3%$40.00+148.4%+226.2%$43.01M$11.54M-13.0950News CoverageEarnings ReportGap DownATNF180 Life Sciences0.5197 of 5 stars$7.27-4.5%N/A+135.8%$42.52MN/A-0.487Gap DownACRVAcrivon Therapeutics2.5769 of 5 stars$1.39+3.0%$17.57+1,164.1%-84.3%$42.47MN/A-0.6258GBIOGeneration Bio3.1844 of 5 stars$6.63+5.4%$10.67+60.9%-74.4%$42.37M$19.89M-0.61150PEPGPepGen3.2342 of 5 stars$1.30+0.8%$7.67+489.7%-86.4%$42.31MN/A-0.4430Gap UpXCURExicure1.8918 of 5 stars$6.55-1.5%N/A+1,455.6%$42.01M$500K-1.6950Gap UpEGRXEagle Pharmaceuticals1.7562 of 5 stars$3.20flatN/AN/A$41.56M$257.55M0.00100 Related Companies and Tools Related Companies Precision BioSciences Alternatives Telomir Pharmaceuticals Alternatives Enlivex Therapeutics Alternatives Sol-Gel Technologies Alternatives 180 Life Sciences Alternatives Acrivon Therapeutics Alternatives Generation Bio Alternatives PepGen Alternatives Exicure Alternatives Eagle Pharmaceuticals Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:LPTX) was last updated on 8/23/2025 by MarketBeat.com Staff From Our PartnersAlex’s “Next Magnificent Seven” stocksThe original “Magnificent Seven” turned $7K into $1.18 million. Now, Alex Green has identified AI’s Next Ma...The Oxford Club | SponsoredElon’s Secret Social Security BombshellTo All Americans Born Before April 16th, 1963: Did Trump Just Give The Green Light To Radically RE-DO Social S...Banyan Hill Publishing | SponsoredThe $7 company helping Nvidia build the world’s first trillion-dollar robot …Michael Robinson has been at the forefront of the technology market for over 40 years. Spotting some profit...Weiss Ratings | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredTrump set to Boost Social Security Checks by 400%?If you're collecting or planning to collect social security... You should see this presentation about Presi...InvestorPlace | SponsoredTrump’s betrayal exposedTrump’s Final Reset Inside the shocking plot to re-engineer America’s financial system…and why you need to ...Porter & Company | SponsoredThe Trump Dump is starting; Get out of stocks now?The first 365 days of the Trump presidency… Will be the best time to get rich in American history.Paradigm Press | SponsoredFed Decision Warning: How to Protect Your Wealth Before September 17th On September 17th, the Fed faces an impossible choice—and Wall Street insiders are already preparing for the...American Alternative | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Leap Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Leap Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
MarketBeat All Access